Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 18/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.34 |
| ▸ | ELOC | Q15369 | 3/20 | 0.32 |
| ▸ | ELOB | Q15370 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22955082 | 1.00 | VHL (0.46) | VHLP2RX3P2RX2ELOCELOB | |
| SCHEMBL25906657 | 0.82 | VHL (0.33) | VHL | |
| SCHEMBL22473792 | 0.82 | VHL (0.47) | VHLP2RX3P2RX2ELOCELOB | |
| SCHEMBL23205424 | 0.81 | VHL (0.48) | VHLP2RX3P2RX2ELOCELOB | |
| SCHEMBL21458942 | 0.80 | VHL (0.52) | VHLP2RX3P2RX2 | |
| SCHEMBL20425319 | 0.80 | VHL (0.52) | VHLP2RX3P2RX2 | |
| SCHEMBL22525599 | 0.79 | VHL (0.58) | VHL | |
| SCHEMBL22526852 | 0.78 | VHL (0.47) | VHLP2RX3P2RX2ELOCELOB | |
| SCHEMBL24440507 | 0.78 | VHL (0.44) | VHLP2RX3P2RX2ELOCELOB | |
| SCHEMBL23986324 | 0.78 | VHL (0.48) | VHLP2RX3P2RX2ELOCELOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023220425-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220129-A1 | BENZOYPARAZINE PYRAZINES ANE THEIR USES | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230132823-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2023-05-04 | — | — | US | disclosed |
| WO-2023069514-A2 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING ITK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2022109426-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2021252666-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021236695-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | MONTELINO THERAPEUTICS, INC. (US) | 2021-11-25 | — | — | WO | disclosed |
| WO-2021222114-A1 | BCL-2 PROTEIN INHIBITORS | RECURIUM IP HOLDINGS, LLC (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2020219650-A1 | DEGRADERS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020210451-A1 | DEGRADERS OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| WO-2020160295-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | MONTELINO THERAPEUTICS, LLC (US) | 2020-08-06 | — | — | WO | disclosed |
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, MDM2, ESRRA | VHL 4/4885P2RX3 4538/4885P2RX2 4567/4885 |
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | VHL 600/4885P2RX3 3331/4885P2RX2 3088/4885 |
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | VHL 1/4885P2RX3 4011/4885P2RX2 3856/4885 |
| US-20230132823-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | VHL 525/4885P2RX3 3738/4885P2RX2 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.